Justin Meiklem

Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel – May 12, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company’s previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed

Rehovot, Israel – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025. Management will host an investor conference call and

Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 Million CDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based Sweeteners Rehovot, Israel – March 31, 2025 – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the

Vancouver, British Columbia and Rehovot, Israel – March 6, 2025 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (NASDAQ: BHST), a company pioneering its patented Botanical Synthesis technology platform, today announcedthat management has been invited to attend the 37th Annual Roth Conference taking place on March 16-18, 2025. CEO Ilan Sobel is scheduled to host

 Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest’s Future Olive Cell Product targeting Liver Health  Vancouver, British Columbia and Rehovot, Israel – March 4, 2025 BioHarvest Sciences Inc.,  (Nasdaq: BHST) (FSE: 8MV0) (“BioHarvest” or “the Company”), a company pioneering its patented Botanical Synthesis technology process, today announced new ‘in